Session Title: Quick Fire Free Paper Session 04
Session Date/Time: Sunday 29/09/2013 | 11:00-13:00
Paper Time: 11:50
Venue: Hall C (Level 1)
First Author: T.Imshenetskaya BELARUS
Co Author(s): I. Igumnova V. Yarmak I. Malinovskaya
To evaluate the effectiveness and safety of the using the single injection bevacizumab (Avastin), injected before surgery in patients with proliferative diabetic retinopathy.
Belarusian Medical Academy of Post-Graduate Education, 10th Minsk City Clinical Hospital, Minsk, Belarus
We studied 18 eyes (13 patients): 7 men (54%) and 6 women (46%) with proliferative diabetic retinopathy, average age 46,3. 7 eyes (38,9%), undergoing surgery for nonclearing vitreous hemorrhage and PDR and 16 eyes (88,9%) - severe PDR and tractional retinal detachment. Intravitreal bevacizumab 1.25 mg/0.05 ml was injected 3 to 5 days before vitrectomy. Standard three port vitrectomy was performed using 20 – or 23 – gauge.
13 eyes (72,3%) underwent PPV and gas infusion (SF6). All cases showed minimum bleeding during pars plana vitrectomy. Recurrent vitreous hemorrhage in the early postoperative period was noted only in one eye (5,6%), increasing of the vitreoretinal traction occurred in 3 eyes (16,7%), traction retinal detachment – in one eye (5,6%). Post-operative BCVA improved in 16,7%.
Preoperative use of bevacizumab in the treatment of severe diabetic retinopathy was well tolerated, reduced active neovascularization, that facilitated pars plana vitrectomy, significantly reduced the occurrence of postoperative vitreous hemorrhage."